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Summary We have recently reported high clinical activity against advanced colorectal cancer of a regimen-alternating bolus FUra,
modulated by methotrexate (MTX), and continuous infusion FUra, modulated by 6-s-leucovorin (6-s-LV). Considering the low toxicity of the
bolus part of this regimen and our recent in vitro finding of a strong synergism between bolus FUra and natural-J-lFN (n-P-lFN), this cytokine
was incorporated in the bolus part of our treatment programme. Fifty-six patients with untreated, advanced, measurable colorectal cancer
were treated with two biweekly cycles of FUra bolus (600 mg m-2), modulated by MTX (24 h earlier, 200 mg m-2), and n-P-lFN (3 x 106 IU i.m.
every 12 h, starting at the time of FUra administration for four doses), alternating with a 3-week continuous infusion of FUra (200 mg m-2
daily), modulated by 6-s-LV (20 mg m-2 weekly bolus). After a 1-week rest, the whole cycle (8 weeks) was repeated if indicated. A total of 5
complete and 17 partial responses were obtained (response rate, 41%; 95% confidence limits, 28-55%) in 54 assessable patients. After a
median follow-up time of 36 months, five patients are still alive. Overall, the median time to treatment failure was 6.4 months. The median
duration of survival was 15.0 months. There was one treatment-related death after a course of MTX -o bolus FUra/n-,B-IFN and grade III-IV
toxicity occurred in 18% of the patients. As the addition of n-J-IFN results in high toxicity, whereas the efficacy seems to be similar to that of
the same regimen without the cytokine, our groups are currently randomizing the original regimen, without IFN, against standard modulated
bolus FUra.
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A substantial improvement has been achieved in the adjuvant treat-
ment of colorectal cancer in recent years (Moertel et al, 1989;
Wolmark et al, 1993; IMPACT investigators, 1995), whereas only
marginal progress havebeen made in the advanced stage (Kemeny,
1995).
As shown in two recent meta-analysis articles (Advanced
Colorectal Cancer Meta-Analysis Project, 1992; Advanced
Colorectal Cancer Meta-Analysis Project, 1994), the addition of
either leucovorin (LV) or methotrexate (MTX) to bolus FUra regi-
mens resulted in a doubling of the response rate compared with
FUra alone. This enhanced activity was not paralleled by a differ-
ence in overall survival with FUra + LV compared with FU alone.
The small, although significant, survival advantage for MTX/FUra
compared with FUra alone confirms the limits of these biochemi-
cally modulated bolus FUra regimens.
Long-term administration of FUra is another rational approach
to improve the activity of this agent and enhanced activity
compared with bolus administration has been shown in several
randomized studies (Lokich et al, 1989; Weinerman et al, 1992;
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Hansen et al, 1996). However, even this approach failed to result in
a survival benefit.
A series of clinical and experimental studies support the hypoth-
esis that FUra has different mechanisms of action depending on the
dose schedule (Aschele et al, 1992; Mori et al, 1993; Sobrero
et al, 1993). Biochemical modulators specific for each schedule
should be used. According to ourpreclinical data, maximal enhance-
ment of bolus FUra is more probably obtained with drugs that
enhance the RNA effect of the fluoropyrimidine, such as MTX,
trimetrexate, phosphonacetyl-L-aspartate, 6-MMPR, whereas LV,
which enhances the thymidylate synthase (TS) inhibitory activity of
FUra, may result ingreaterpotentiation when thefluoropyrimidine is
administered as acontinuous infusion (Sobrero et al, 1997a).
This approach was tested in a phase II clinical study at the
Istituto Nazionale per la Ricerca sul Cancro of Genoa. A regimen
alternating two biweekly cycles ofbolus FUra, preceded by MTX,
with a 3-weekcontinuous infusion ofFUra, modulatedby low dose
LV, resulted in a 48% objective response rate, 9.5 months progres-
sion free survival (PFS) and 20.2 months overall survival on a
series of33 advanced colon cancerpatients (Sobrero et al, 1995).
The low toxicity ofthe bolus part ofthis regimen along with our
recent in vitro finding ofselective potentiation ofpulse FUra by n-
,B-IFN (Guglielmi et al, 1995), prompted us to incorporate the
cytokine in the bolus part ofour programme to maximize the clin-
ical activity. The dose and timing of IFN administration were
chosen on the basis of our in vitro data: exposure ofhuman colon
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cancer cells (HCT-8) to low-dose n-p-IFN for up to 24 h after a
short-term exposure to FUra results in enhanced incorporation of
the fluoropyrimidine into nucleic acids and enhanced cell kill
(Guglielmi et al, 1995). Natural-,-IFN was thus given for only 2
days after bolus FUra administration and a low dose was used (3 x
106 IU twice daily). This leaves the infusional part of the original
regimen unchanged and only four i.m. IFN administrations are
added to each course of MTX/bolus FUra. A further objective of
this clinical trial was to define the activity of schedule-dependent
biochemical modulation in a multi-institution setting, before a
randomized comparison with standard modulated bolus FUra.
MATERIALS AND METHODS
Eligibility criteria
Fifty-six patients with biopsy-proven, relapsed or metastatic
adenocarcinoma of the colon or rectum, referred to the Istituto
Nazionale per la Ricerca sul Cancro (Genoa, Italy), the Istituto
Oncologico Romagnolo (Forli, Italy) or the Ospedale S. Carlo
Borromeo (Milan, Italy) were accrued into this three institution
phase II trial from October 1993 to December 1994. The disease
had to be measurable, with appropriate radiological examinations
obtained no longer than 1 month before the beginning of treat-
ment. No previous chemotherapy for metastatic disease was
allowed and adjuvant chemotherapy should have been completed
more than 1 year before study entry. Radiation therapy was
allowed, as long as it did not encompass the indicator lesions.
Adequate bone marrow (granulocyte and platelet counts greater
than 1500 mm-3 and 100 000 mm-' respectively), hepatic (serum
bilirubin < 3.0 mg dl-1, aspartate and alanine aminotransferases
less than three times the upper limits ofnormal) and renal (creati-
nine levels < 1.7 mg dl-1) function was required. ECOG perfor-
mance status had to be < 2 and life expectancy greater than 3
months. Additional eligibility criteria included geographic acces-
sibility, the absence of clinically relevant ascites and the absence
ofother medical conditions clearly contraindicating the delivery of
any chemotherapy.
This study was approved by the ethics committee ofthe Istituto
Nazionale per la Ricerca sul Cancro of Genoa and informed
consent was obtained before study entry.
TREATMENT PLAN
Sequential methotrexate -> bolus FUra + n-3-IFN were used alter-
nately with prolonged continuous infusion (CI) FUra modulated
by 6-S-LV. Figure 1 illustrates the regimen. The bolus part of the
treatment programme consisted of two biweekly administrations
ofbolus FUra given i.v. at 600 mg m-2 (day 2 and 16), modulated
by MTX, given 24 h earlier at 200 mg m-2(day 1 and 15), andn-p-
IFN, administered i.m. at 3 x 106 IU every 12 h x 4, starting at the
time ofFUra administration (days 2-3 and 16-17). 6-S-LV, 10 mg
m-2 p.o. every 6 h x 6, was given on days 2 and 16, starting after
bolus FUra administration, as a rescue from MTX toxicity. To
prevent or attenuate the severity offlu-like syndrome, the patients
were instructed to take acetaminophen, 500 mg p.o., 30 minbefore
each IFN administration. After a 2-week rest, a 3-week prolonged
infusion of FUra at 200 mg m-2 day-' was started (day 29-50),
modulated by weekly boluses of6-S-LV at 20 mg m-2 (day 29, 36
and 43). The cycles were repeated after 1 week of rest (day 57),
provided that the patient had recovered from toxicity. The entire














Previous adjuvant chemotherapy 10 (18)
Sites of disease
Liver only 33 (59)
Liver and other sites 10 (18)
Lung 3 (5)
Intra-abdominal 10 (18)
duration of one cycle is thus 8 weeks. CI FUra was administered
through an implanted catheter and a venous Port-a-cath
(Pharmacia) connected to a portable programmable external pump
(CADD-1, Pharmacia).
Toxicity was evaluated according to World Health Organization
(WHO) criteria (World Health Organization, 1979) on days 15, 29,
36, 43, 50 and 57. Complete blood counts were obtained on the
same days. Liver function tests, blood urea nitrogen, creatinine
and electrolytes were obtained monthly.
Dose modification criteria for the MTX -* FUra + IFN regimen
were as follows: no dose reduction for gastrointestinal grade I and
II toxicity; for grade III diarrhoea or mucositis, the treatment was
delayed until recovery and the doses ofMTX and FUra ofthe next
cycle were decreased by 50%; the dose was reduced by 50% for a
WBC of < 3000 mm-3 or platelets < 75 000 mm-3 on the day of
recycling; treatment was discontinued in case ofgrade IV toxicity;
the dose of IFN was not reduced for myelotoxicity, diarrhoea or
mucositis unless toxicity was not overcome by reducing the MTX
and FUra doses; the dose of IFN was reduced by 50% for severe
constitutional symptoms (fatigue, malaise and anorexia).
CI FUra was discontinued at the first signs of mucositis and/or
palmar-plantar dysaesthesia/burning, and resumed when these
symptoms abated. In the case of severe (grade III) mucositis, the
infusion was resumed at a reduced FUra dose (50%). The dose of
LV during the infusional treatment was not modified in this study.
Response evaluation
Patients who had received at least 2 months oftherapy (one cycle)
with adequate pretreatment and follow-up radiographic studies
were considered assessable for response, as were patients who
experienced rapid disease progression after at least two courses of
bolus FUra.
Objective responses were evaluated according to WHO criteria
(Miller et al, 1981) after each cycle of treatment (2 months); the
baseline areas of the indicator lesions (cm2) and their variations at
each successive cycle were reported.
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MTX - * FUra/n-1-IFN
I
day 15 days 16-17
days 29-50 FUra Cl
6-S-LV 6-S-LV 6-S-LV
day 29 day 36 day 43
Figure 1 Design of drug regimen. One cycle = 8 weeks. In the first part of the cycle, patients were given MTX 200 mg m-2 i.v. diluted in 500 ml of D5W, infused
in 1 h, day 1; FUra 600 mg m-2 i.v. bolus, day 2; (6S)LV, 10 mg m-2 p.o. every 6 h x 6, days 2-3, starting after FUra bolus; and n-f-lFN 3 x 106 IU i.m. every
12 h x 4, days 2-3. In the second part of the cycle, patients were given FUra, 200 mg m-2, day 1 Cl x 3 weeks, and (6S)LV, 20 mg m-2 i.v. bolus every week
At the end ofthe study (54 patients), more than 27 responses were
required to consider the regimen including n-p-IFN for additional
studies, whereas IFN hadtobedroppedif27 responses orless were
seen. The time to treatment failure (lTFF) was measured from the
initiation oftherapy until the date ofdisease progression as defined
above or discontinuation of therapy for toxicity or refusal. The
probability of treatment failure and survival was calculated using
the Kaplan-Meier method (Kaplan and Meier, 1958). The associa-
tion between performance status and the proportion of responses
was assessed using the Mantel test for trend (Mantel, 1963).
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Figure 3 Kaplan-Meier survival curve for all 56 patients. Fifty-one patients
have died
Dose intensity
Delivered dose intensity for bolus FUra and for CI FUra was
expressed in terms of mg m-2 per week.
Statistical methods
A 48% response rate was obtained in the previous phase II trial of
our regimen with 95% confidence limits at 31 and 66% (Sobrero et
al, 1995). Ifthe addition ofIFN increases this activity, an interesting
target level forthe response rate is 60%. The study was thus planned
to have a less than 10% probability ([ error = 0.10) ofrejecting the
regimen ifthe true response rate is at least 60% (P1) and a less than
5% probability (a error = 0.05) ofaccepting the regimen for further
studies ifthe true response rate is less than 40% (P0).
A two-stage study was planned according to Simon's minimax
design (Simon et al, 1989). More than 12 responses had to occur
among the first 29 patients (I stage) to proceed to the second stage.
RESULTS
Patient characteristics
Between October 1993 and December 1994, 56 patients meeting
the eligibility criteria were registered at the three participating
Institutions.
Table 1 shows patient characteristics. Ten (18%) patients had
received previous adjuvant chemotherapy: fourhad received FUra-
LV, 5 FUra-levamisole and 1 FUra-LV-levamisole.
Thirty-three (59%) patients had liver metastases only, whereas
ten (18%) had liver disease plus other sites of metastases. Among
the patients without liver involvement, three had lung metastases
and ten had extrahepatic intra-abdominal masses as measurable
sites.
The median time between diagnosis of metastatic disease and
study entry was 40 (range 5-237) days.
Lesions were measured by CT scan in 43 patients and ultra-
sound in seven patients the remainder being measured by chest
radiography and nuclear magnetic resonance. Only eight patients
had lesions less than 2 x 2 cm and the median measured baseline
tumour area was 35 (range 2-358) cm2. The median number of
tumour lesions evaluated per patient was three (range 1-7) and
eight patients had only one lesion measured.
All patients were assessable for toxicity. Fifty-four patients
were considered assessable for response. Onepatient was excluded
from response assessment because measurements were not avail-
able for the tumour lesions detected in the baseline liver ultra-
sound. The otherpatient hadenlarged supraclavicularlymph nodes
as the only site ofmetastatic disease. Measurements were obtained
by physical examination only, rather than radiographic imaging as
specified by the protocol. This patient was therefore not included
in the response analysis, despite a reduction in tumour mass
assessed by physical examination and a greater than 50% reduc-
tion in CEA levels. The time to disease progression in this patient
was 8 months and he is still alive at 27 months. All patients were
included in the analysis ofTTF and survival.
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Table 2 Clinical toxicity: worst WHO grade per patient across all cycles (n= 56 patients)
MTX -* FUra + ,B IFN Cl FUra + 6-S-LV
toxicity grade (%) toxicity grade (%)
Toxicity I II IlIl IV I II IlIl IV
Mucositis 27 9 7 2 21 34 9 -
Diarrhoea 25 4 4 - 14 1 1 9
Nausea/vomiting 53 12 - - 30 7 -
Asthenia 21 20 2 - 11 5 2
Fever/myalgia 18 37 2 - 9 4 -
Anaemia 16 7 - - 4 4
Thrombocytopenia - - 2 4 2 - - -
Leucopenia 7 5 2 5 2 - - -
Conjunctivitisa 32 - - - 28 - - -
Hand-foot syndromea 12 - - - 30 - - -
aScored as grade 1 if present.
Treatment outcome
Five complete responses (CRs) and 17 PRs were observed among
the 54 patients considered assessable for response, for an overall
response rate of41% (95% confidence interval, 28-55%). Ifall the
56 patients are included, the response rate was 39%. In addition, a
substantial percentage of patients (39%) had a minor response or
stable disease with a median duration of 4.5 (range 2.0-9.2)
months. Eleven failures were reported: five patients progressed
after the first cycle of treatment, three patients showed a rapid
disease progression before the end of the first cycle and three
patients had the treatment interrupted after the first two courses of
bolus FUra because ofgrade IV toxicity.
The median time to achieve a partial or complete response was
58 (range, 49-220) days, with initial responses attained after one
cycle (ten cases), two cycles (seven cases) and three cycles (five
cases). Half of the responding patients showed continued tumour
shrinkage and the median time to achieve the maximum clinical
response was 130 (range 54-287) days.
Four out of five patients with complete response had liver
disease only, with multiple inoperable metastases (two, three, three
and six measured lesions respectively); the other patient had three
lung lesions as the only site of metastatic disease. Two of the
patients with liver disease underwent surgical exploration 2 and 6
months after achieving the complete response respectively. No
residual disease was found in the first patient who is still alive and
disease-free at 40 months. A peritoneal dissemination (multiple
unresectable peritoneal nodules) was revealed in the second
patient who had failed at this point (CR duration 6 months) and
died 5 months later. The other complete responses lasted 8, 9 and
13 months.
Only 4 out ofthe 22 responses were obtained in patients with 2
metastatic sites (liver + pelvic masses), the rest being liver only
(15 patients), lung only (one patient) and extrahepatic intra-
abdominal disease (two patients).
Previous adjuvant treatment appeared to influence the clinical
response: one out often patients who had received adjuvant treat-
ment responded (10% response rate), whereas 21 responses were
observed among the 44 patients who had not received previous
adjuvant chemotherapy (48% response rate, P = 0.038).
The combined CR and partial response (PR) rate was 54%, 29%
and 20% in patients with an ECOG PS of 0,1 and 2, respectively
(%2 = 3.755, P =0.052, two-tailed Mantel test fortrend), suggesting
that initial PS affects treatment outcome as reported earlier.
Age and primary site did not appear to influence the overall
clinical response (47% and 37% inpatients younger and olderthan
60 years of age; 42% and 36% in patients with colon or rectal
primaries).
The median duration of response was 6.8 (range, 2-40+)
months.
All patients are now off treatment. Three patients declined
further chemotherapy while they were still responding; they were
considered treatment failures as of the date the treatment was
discontinued. The patient that achieved a pathological CR is still
disease-free; all the rest have progressed. With a median follow-up
time of 36 months, 51 deaths have occurred. The median TTF
(Figure 2) for the whole cohort of 56 patients was 6 (range 0-40)
months and the median survival time (Figure 3) was 15.0 (range
0-40) months.
Dose delivery and toxicity
One-hundred and fifty-six cycles of treatment (2 months each)
were administered, with a median of three cycles (range 0-5) per
patient. The number of 'bolus' FUra administrations (309) is
consistent with the total number of cycles administered. The
number ofweeks ofCI FUra (410) is slightly lower than expected.
Eighteen cycles consisted ofless than 3 weeks ofCI FUra because
oftoxicity (11 cycles), catheter-related complications (four cycles)
and patient refusal (three cycles). In addition, progression was
documented and treatment discontinued before or during the infu-
sional part ofthe regimen in ten cycles.
Ten (3.2%) of 309 'bolus FUra' administrations were given at
reduced doses because of toxicity related to the previous courses.
Thirty-five (8.5%) of410 weeks ofCI FUra were administered for
less than 7 days and/or at reduced doses because of toxicity (27
weeks) or other reasons including catheter-related complications,
disease progression and patient request (8 weeks).
It has been reported that FUra dose intensity may affect treat-
ment outcome. In the current study, no substantial differences
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between responders and non-responders were detected in the
median FUra dose intensity (mg m-2 per week) actually delivered
for the first two cycles of treatment: 271 (range 103-311) vs 278
(range 190-295) for the 'bolus part' (n = 43) and 848 (range
350-1131) vs 835 (range 126-1025) forthe CI part (n = 40). These
figures did not change substantially throughout the treatment. The
median delivered FUra dose intensity over all cycles of therapy
was 289 mg mi-2 per week for the 'bolus part' (range 103-320) and
924mg m-2 per week for the CI part (range 135-1131). These
values represent 96.3% and 88% of planned dose intensity values
respectively.
Table 2 reports the worst toxicity of each type, suffered by each
patient, across all cycles. The two parts of the regimen are consid-
ered separately. One toxic death was reported after a course ofbolus
FU modulated with MTX and ,B-IFN (grade IV leucopenia, throm-
bocytopenia and mucositis with septic shock). In this part of the
programme, severe or life-threatening toxicity occurred in 14% of
thepatients (leucopenia, mucositis anddiarrhoea). Grade IV toxicity
was notreported during the infusional part ofthe regimen. A total of
18% ofthepatients experienced grade III mucositis and/ordiarrhoea
during the administration ofCI FUra. A total of39% ofthe patients
experienced mild to moderate flu-like syndrome in the bolus part of
the programme, leading to a reduction ofthe n-,-IFN dose in three
patients. Hand-foot syndrome was much moreprominent during the
infusional treatment (30% of patients), whereas conjunctivitis was
observed only after several months of treatment and could not be
attributed to either of the two schedules. Only three patients (5%)
had catheter-related complications requiring admission to hospital:
one with sepsis and two with thrombosis.
DISCUSSION
The use of biochemical modulators specific for each schedule of
FUra administration along with the alternate use of bolus and CI
FUra represents a novel strategy to improve the efficacy of the
fluoropyrimidine. This approach resulted in high clinical activity
in a recent phase II trial of a regimen alternating bolus FUra,
modulated by MTX, and CI FUra, modulated by low-dose 6-s-LV
(Sobrero et al, 1995).
This strategy is based on a series of experimental and clinical
findings: (a) repeated short-term exposures ofhuman colon cancer
cells to FUra in vitro produced resistance via an RNA-related
mechanism, whereas resistance to long-term exposures was medi-
ated by a TS-directed mechanism (Aschele et al, 1992); (b) in the
same in vitro model, cells resistant topulse FUra maintained sensi-
tivity to prolonged exposures to the fluoropyrimidine (Sobrero et
al, 1993); and (c) patients progressing during treatment with bolus
FUra were not completely resistant to CI FUra (Mori et al, 1993).
These findings suggested that FUra may have two different modes
of action depending on the schedule of administration. Bolus and
CI FUra may thus be alternated to prevent or delay the develop-
mentofdrug resistance and itmay bepossible to selectively modu-
late each schedule biochemically. According to our preclinical
data, potentiation of FUra by LV may be maximal when the fluo-
ropyrimidine is given for prolonged periods oftime whereas chan-
nelling FUra into RNA using MTX may improve results when a
short-term, high dose is used (Sobrero et al, 1997b).
The present study was designed to test whether the addition of
n-p-IFN could further enhance the activity ofthe original regimen.
Natural P IFN was used on the basis ofexperimental data showing
synergistic interactions with FUra on human colon cancer cells in
vitro (Guglielmi et al, 1995). In this experimental system, n -IFN
had stronger cytotoxic effects compared with a-IFN (Guglielmi et
al, 1995). In addition, six randomized studies failed to demonstrate
a significant improvement in response rate or survival in patients
treated with FUra (± LV) + a-IFN compared with bolus FUra
alone, CI FUra alone or bolus FUra + LV (Corfu - A Study Group,
1995; Hill et al, 1995a, b; Greco et al, 1996; Kosmidis et al, 1996;
Seymour et al 1996). Preliminary clinical data had been reported
on the use of,B-IFN as FUra modulator: substantial clinical activity
and low toxicity were obtained in a series of clinical trials on
advanced colorectal cancer patients (Wadler et al, 1995).
Our in vitro data also provided the rationale for the selective
addition ofthe cytokine in the bolus part ofthe original regimen as
well as for the timing and duration of IFN administration. The
synergism obtained in vitro was strictly dependent on FUra sched-
uling with long-term exposures to the fluoropyrimidine resulting
in loss of the synergistic interactions observed with short-term
exposures (Guglielmi et al, 1995). Biochemical studies indicated
that exposure to low-dose IFN for up to 24 h after a short-term
exposure to FUra resulted in enhanced incorporation of the
fluoropyrimidine into nucleic acids (Guglielmi et al, 1995). On
this basis, IFN was only given for 2 days afterbolus FUra adminis-
tration and a low dose was used (3 x 106 IU twice daily).
Despite the sound preclinical rationale, the addition of n-,-IFN
does not appear to improve the therapeutic outcome compared
with the original regimen. The response rate, median TTF and
median overall survival in the current study are slightly lower than
our previous phase II study (Sobrero et al, 1995). As this was not
a randomized comparison, a different distribution of prognostic
factors affecting the clinical response to FUra between the patient
populations of the two studies may contribute to explain these
results. In the study reported here, four patients were found to have
brain metastases leading to treatment discontinuation within the
first cycle, while brain involvement was a later event in the
previous trial. In addition, the percentage of patients that previ-
ously received adjuvant therapy is double that in our previous
study. However, the main patient characteristics, including median
age and PS, the percentage ofpatients asymptomatic or minimally
symptomatic, the measured baseline tumour area and the sites of
measurable disease, were similar between the two studies. It is
thus reasonable to infer from the results of this trial that further
selective anti-tumour modulation ofbolus FUra byn-p-IFN is not
obtained at the clinical level.
Even although the addition of IFN does not seem to improve the
outcome ofourregimen, the results reported here show a substantial
activity of schedule-oriented biochemical modulation. The 15
months in median survival time along with a 41% response rate in
56 patients accrued at three different institutions, compares well
with the best reported results of modulated FUra regimens. The
durability of CRs and PRs is also promising. Our group has thus
discarded n-[B-IFN but has maintained the original alternating
regimen as the experimental arm ofa currently ongoing randomized
trial comparing schedule selective biochemical modulation vs stan-
dard modulated bolus FUra. Preliminary response data (34% vs.
12%, P = 0.001) and TTF (6.2 months vs. 4.1 months, P = 0.01) are
extremely promising (Sobrero et al, 1997b; Frassineti et al, 1997).
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